ORIC Pharmaceuticals
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | - | 16.2m |
| EBITDA | (24.5m) | (78.9m) | (81.8m) | (110m) | (139m) | (153m) | (131m) |
| % EBITDA margin | - | - | - | - | - | - | (811 %) |
| Profit | (73.7m) | (78.7m) | (89.1m) | (101m) | (125m) | (156m) | (175m) |
| % profit margin | - | - | - | - | - | - | (1082 %) |
| EV / revenue | - | - | - | - | - | - | 45.2x |
| EV / EBITDA | -50.6x | -7.3x | -3.2x | -2.4x | -5.3x | -4.8x | -5.6x |
| R&D budget | 35.9m | 56.9m | 61.7m | 85.2m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$15.0m | Series A | ||
| N/A | $53.0m | Series B | |
$50.0m | Series C | ||
$55.0m | Series D | ||
| N/A | N/A | IPO | |
* | $25.0m | Post IPO Equity | |
* | $85.0m | Post IPO Equity | |
* | $4.7m | Post IPO Equity | |
| Total Funding | CAD236m | ||
Related Content
Recent News about ORIC Pharmaceuticals
EditORIC Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies to overcome resistance in cancer treatment. The company's lead product candidate, ORIC-101, is a glucocorticoid receptor (GR) antagonist currently in Phase 1b clinical trials. GR is often overexpressed in multiple solid tumors and is associated with poorer outcomes, making it a critical target for cancer therapy. By blocking GR activity, ORIC-101 aims to improve patient outcomes and combat resistance to existing treatments.
ORIC Pharmaceuticals operates in the oncology market, primarily serving patients with advanced or metastatic solid tumors. The company employs a research-driven business model, investing heavily in preclinical and clinical trials to validate its therapeutic candidates. Revenue is generated through partnerships, licensing agreements, and potential future sales of approved therapies.
The company is also exploring other promising candidates, such as a CD73 inhibitor, to further expand its pipeline. ORIC Pharmaceuticals aims to address significant unmet medical needs in oncology by targeting the underlying mechanisms of resistance.
Keywords: oncology, cancer treatment, resistance mechanisms, glucocorticoid receptor, GR antagonist, ORIC-101, clinical trials, biopharmaceutical, CD73 inhibitor, metastatic tumors.